Blood purification and mortality in sepsis: A meta-analysis of randomized trials

Critical Care Medicine

Volumn 41, Issue 9, 2013, Pages 2209-2220

  Zhou, Feihu ^a,b   Peng, Zhiyong ^a   Murugan, Raghavan ^a   Kellum, John A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

blood purification; cytokines; inflammation; metaanalysis; mortality; sepsis

Indexed keywords

ANTIBIOTIC AGENT; FRESH FROZEN PLASMA; NORADRENALIN; POLYMYXIN B;

ACUTE KIDNEY FAILURE; APACHE; APHERESIS; BLOOD FILTRATION; BLOOD PURIFICATION; COCHRANE LIBRARY; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; DATA BASE; DISEASE SEVERITY; EMBASE; HEMODIAFILTRATION; HEMODIALYSIS; HEMOFILTRATION; HEMOPERFUSION; HUMAN; HYPOTENSION; MEDLINE; META ANALYSIS; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SURVIVAL TIME; SYSTEMATIC REVIEW; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

CAUSE OF DEATH; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SORPTION DETOXIFICATION;

EID: 84883654315     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31828cf412     Document Type: Review

References (50)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
2. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 48:1546-1554
3. Xigris [drotrecogin alfa (activated)]: Market Withdrawal-Failure to Show Survival Benefit. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm277143.htm. Accessed January 15, 2013.
4. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34:17-60
5. Joannidis M: Continuous renal replacement therapy in sepsis and multisystem organ failure. Semin Dial 2009; 22:160-164
6. Graziani G, Bordone G, Bellato V, et al; Gruppo di Studio Trattamenti depurativi in area critica of the Italian Society of Nephrology: Role of the kidney in plasma cytokine removal in sepsis syndrome: a pilot study. J Nephrol 2006; 19:176-182
7. Kellum JA, Kong L, Fink MP, et al; GenIMS Investigators: Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167:1655-1663
8. Gogos CA, Drosou E, Bassaris HP, et al: Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options. J Infect Dis 2000; 181:176-180
9. Peng Z, Pai P, Han-Min W, et al: Evaluation of the effects of pulse high-volume hemofiltration in patients with severe sepsis: A preliminary study. Int J Artif Organs 2010; 33:505-511
10. Honore PM, Joannes-Boyau O, Boer W, et al: High-volume hemofiltration in sepsis and SIRS: Current concepts and future prospects. Blood Purif 2009; 28:1-11
11. Boussekey N, Chiche A, Faure K, et al: A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med 2008; 34:1646-1653
12. Haase M, Silvester W, Uchino S, et al: A pilot study of high-adsorption hemofiltration in human septic shock. Int J Artif Organs 2007; 30:108-117
13. Morgera S, Haase M, Kuss T, et al: Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006; 34:2099-2104
14. Ronco C, Brendolan A, Lonnemann G, et al: A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002; 30:1250-1255
15. Honore PM, Jamez J, Wauthier M, et al: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28:3581-3587
16. Ghani RA, Zainudin S, Ctkong N, et al: Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrology (Carlton) 2006; 11:386-393
17. Cole L, Bellomo R, Hart G, et al: A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30:100-106
18. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17:1-12
19. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg 2010; 8:336-341
20. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560
21. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188
22. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634
23. Huang Z, Wang SR, Su W, et al: Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial 2010; 14:596-602
24. Peng Y, Yuan Z, Li H: Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis. Burns 2005; 31:623-628
25. Nakamura T, Kawagoe Y, Matsuda T, et al: Effect of polymyxin B-immobilized fiber on bone resorption in patients with sepsis. Intensive Care Med 2004; 30:1838-1841
26. Nakamura T, Ushiyama C, Suzuki Y, et al: Hemoperfusion with polymyxin B-immobilized fiber in septic patients with methicillin-resistant Staphylococcus aureus-associated glomerulonephritis. Nephron Clin Pract 2003; 94:c33-c39
27. Nakamura T, Ushiyama C, Suzuki Y, et al: Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus. J Hosp Infect 2003; 53:58-63
28. Busund R, Koukline V, Utrobin U, et al: Plasmapheresis in severe sepsis and septic shock: A prospective, randomised, controlled trial. Intensive Care Med 2002; 28:1434-1439
29. Nakamura T, Ushiyama C, Suzuki Y, et al: Hemoperfusion with polymyxin B immobilized fibers for urinary albumin excretion in septic patients with trauma. ASAIO J 2002; 48:244-248
30. Nemoto H, Nakamoto H, Okada H, et al: Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 2001; 19:361-369
31. Cruz DN, Antonelli M, Fumagalli R, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial. JAMA 2009; 301:2445-2452
32. Payen D, Mateo J, Cavaillon JM, et al; Hemofiltration and Sepsis Group of the Collège National de Réanimation et de Médecine d'Urgence des Hôpitaux extra-Universitaires: Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: A randomized controlled trial. Crit Care Med 2009; 37:803-810
33. Vincent JL, Laterre PF, Cohen J, et al: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23:400-405
34. Reinhart K, Meier-Hellmann A, Beale R, et al; EASy-Study Group: Open randomized phase II trial of an extracorporeal endotoxin adsorber in suspected Gram-negative sepsis. Crit Care Med 2004; 32:1662-1668
35. Reeves JH, Butt WW, Shann F, et al: Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 1999; 27:2096-2104
36. Nakamura T, Ebihara I, Shoji H, et al: Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: Decrease in plasma levels of soluble P-selectin, platelet factor 4 and beta-thromboglobulin. Inflamm Res 1999; 48:171-175
37. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
38. Cornejo R, Downey P, Castro R, et al: High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006; 32:713-722
39. Bellomo R, Kellum JA, Gandhi CR, et al: The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 2000; 161:1429-1436
40. Jun M, Heerspink HJ, Ninomiya T, et al: Intensities of renal replacement therapy in acute kidney injury: A systematic review and metaanalysis. Clin J Am Soc Nephrol 2010; 5:956-963
41. Van Wert R, Friedrich JO, Scales DC, et al; University of Toronto Acute Kidney Injury Research Group: High-dose renal replacement therapy for acute kidney injury: Systematic review and meta-analysis. Crit Care Med 2010; 38:1360-1369
42. Peng ZY, Wang HZ, Carter MJ, et al: Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int 2012; 81:363-369
43. Boomer JS, To K, Chang KC, et al: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306:2594-2605
44. Lin YF, Ko WJ, Chu TS, et al; NSARF Study Group: The 90-day mortality and the subsequent renal recovery in critically ill surgical patients requiring acute renal replacement therapy. Am J Surg 2009; 198:325-332
45. Brar H, Olivier J, Lebrun C, et al: Predictors of mortality in a cohort of intensive care unit patients with acute renal failure receiving continuous renal replacement therapy. Am J Med Sci 2008; 335:342-347
46. Sakamoto Y, Mashiko K, Obata T, et al: Effectiveness of continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter after polymyxin B-immobilized fiber column therapy of septic shock. ASAIO J 2008; 54:129-132
47. Yonekawa C, Nakae H, Tajimi K, et al: Combining continuous endotoxin apheresis and continuous hemodiafiltration in the treatment of patients with septic multiple organ dysfunction syndrome. Ther Apher Dial 2006; 10:19-24
48. LeLorier J, Grégoire G, Benhaddad A, et al: Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337:536-542
49. Kellum JA, Uchino S: International differences in the treatment of sepsis: Are they justified? JAMA 2009; 301:2496-2497
50. Langgartner J, Vasold A, Glück T, et al: Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med 2008; 34:1091-1096